Disease Landscape and Forecast Insights

Clarivate’s Extrapolated Worldwide Coverage is the first and only evidence-based data set of epidemiological forecasts for key hypertension patient populations, covering 171 countries and more…

Clarivate Epidemiology’s coverage of hypertension comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of hypertension for each…

Clarivate Epidemiology’s coverage of hypertension comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of hypertension for each…

Clarivate Epidemiology’s coverage of hypertension comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of hypertension for each…

Clarivate Epidemiology’s coverage of hypertension comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of hypertension for each…

Clarivate Epidemiology’s coverage of hypertension comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of hypertension for each…

Clarivate Epidemiology’s coverage of hypertension comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of hypertension for each…

Pulmonary hypertension (PH) is a devastating disease with high levels of morbidity and mortality, and no cure. Despite the rarity of the disease, the potential commercial opportunities for drugs…

Pulmonary arterial hypertension (PAH) is a rare, life-threatening disorder marked by considerable morbidity and mortality. Despite the availability of a wide array of drugs for PAH, substantial…

Pulmonary arterial hypertension (PAH) is a rare, life-threatening disorder characterized by high blood pressure in the arteries of the lungs. It is a progressive condition marked by considerable…

Pulmonary hypertension (PH) constitutes a group of rare diseases, including pulmonary arterial hypertension (PAH), yet the commercial potential for novel drugs approved for PH indications is…

Clarivate Epidemiology’s coverage of pulmonary hypertension (PH) comprises epidemiological estimates of key patient populations in 14 mature and emerging pharmaceutical markets worldwide. We…